Pfizer Falls on Celebrex News

AstraZeneca shares drop on unfavorable cancer-drug study; PalmOne declines on lowered third-quarter guidance; plus more of Friday's stocks in the news

Pfizer (PFE ) shares fell Friday after a delayed opening. Regarding the cardiovascular safety of its COX-2 inhibitor Celebrex based on 2 cancer trials, Pfizer says 1 trial (Adenoma Prevention with Celecoxib) showed increased cardiovascular risk vs. placebo; the other showed no greater risk.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.